About Cres Genomic
Cres Genomic is a Healthcare company based in Madrid (Spain) founded in 2014. It delivers comprehensive stem-cell-based regenerative technologies for healthcare challenges. It operates on a B2B model. Its focus areas include Biotechnology, Regenerative Medicine and Stem-Cell Technologies. Similar companies include Everlywell, Viome, Color, Invitae and Counsyl and 4 more; 9 of its 9 listed similar companies have raised funding.
Company details
Cres Genomic, based in Madrid, focuses on providing healthcare solutions, advancing biotech innovations, regenerative medicine, and stem-cell technologies. Delivers comprehensive stem-cell-based regenerative technologies for healthcare challenges. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
- Headquarters Madrid, Spain
- SectorsHealthcare
- Website cresgenomic.com
- Social X Facebook
Similar companies to Cres Genomic
Cres Genomic has 9 listed similar companies in our database, 9 of them funded. They include Everlywell, Viome, Color, Invitae and Counsyl, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| everlywell.com | 2014 | Austin, United States | $330M | 614 | At-home health tests for biomarkers, nutrition, and hormone analysis. | |
| viome.com | 2016 | Los Alamos, United States | $301.57M | 136 | Machine learning-based bioinformatics solutions for health insights are provided. | |
| color.com | 2013 | Burlingame, United States | $491.44M | 687 | Cancer care is delivered through a virtual clinic by Color. | |
| invitae.com | 2010 | San Francisco, United States | $189.56M | 1,700 | Home-based genetic tests for detecting diseases are provided to individuals. | |
| counsyl.com | 2007 | San Francisco, United States | $112.89M | 503 | DNA mapping for pre-pregnancy genetic testing, DNA and cancer screening | |
| variantbio.com | 2018 | Brooklyn, United States | $127.74M | – | Personalized therapeutics are developed using genomic data for rare diseases. | |
| geneplanet.com | 2008 | Ljubljana, Slovenia | $34.02M | – | DNA-based personalized health and fitness recommendations are offered. | |
| newtopia.com | 2008 | New York, United States | $13.1M | – | Health management platform is provided for employers and insurers. | |
| digbihealth.com | 2018 | Mountain View, United States | $5.4M | – | Personalized healthcare is delivered through DNA and gut biome testing. |
Detailed similar companies of Cres Genomic
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
10 companies that operate in the same segment as Cres Genomic (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 253 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cres Genomic
Cres Genomic was founded in 2014.
Cres Genomic is headquartered in Madrid, Spain. It is registered at Madrid, Madrid, Spain.
Cres Genomic, based in Madrid, focuses on providing healthcare solutions, advancing biotech innovations, regenerative medicine, and stem-cell technologies. Delivers comprehensive stem-cell-based regenerative technologies for healthcare challenges. The company prioritizes operational excellence, innovation, and customer-centric approaches for success. It continues to evolve, meeting industry challenges with strategic approaches.
Cres Genomic's top competitors include Viome, Variant Bio and Newtopia.